|1.||Cannon, Christopher P: 42 articles (09/2015 - 04/2002)|
|2.||Jukema, J Wouter: 31 articles (09/2015 - 11/2002)|
|3.||Ford, Ian: 31 articles (08/2015 - 11/2002)|
|4.||Shepherd, James: 27 articles (02/2012 - 03/2002)|
|5.||Braunwald, Eugene: 27 articles (06/2011 - 03/2002)|
|6.||Westendorp, Rudi G J: 21 articles (09/2015 - 11/2002)|
|7.||Ohashi, Yasuo: 21 articles (08/2014 - 01/2005)|
|8.||de Craen, Anton J M: 19 articles (09/2015 - 08/2005)|
|9.||Sacks, Frank M: 18 articles (07/2014 - 03/2002)|
|10.||Nakamura, Haruo: 18 articles (01/2014 - 01/2005)|
06/14/1993 - "Pravastatin treatment of hypercholesterolemia is highly effective and well tolerated alone and in combination with bile acid-binding resin and shows no tendency to increase muscle enzyme levels."
09/01/1994 - "These results indicate that long-term administration of pravastatin is beneficial in the treatment of hypercholesterolemia in elderly patients."
05/01/1996 - "This combination may be useful and more cost-effective in elderly patients with hypercholesterolemia, who might have a higher incidence of side effects when using larger doses of pravastatin alone."
12/01/1990 - "Once-daily pravastatin is a safe and effective treatment for patients with primary hypercholesterolemia and has a favorable safety profile."
06/01/1994 - "In this study, pravastatin was well tolerated and effective in lowering LDL-C, Total-C, and TG and in raising HDL-C during long-term treatment of elderly patients with primary hypercholesterolemia."
06/01/1995 - "These data lead to the conclusion that pravastatin is useful for the treatment of hyperlipidemia in type 2 diabetic patients with poor glycemic control without major adverse effects."
06/03/1998 - "The combination of pravastatin and HRT in the management of hyperlipidemia in postmenopausal women is very useful therapeutically, because it additionally provides the broad benefits of HRT, without compromising the lipid lowering effects of either treatment."
01/01/2000 - "The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is designed to determine all-cause mortality for subjects receiving pravastatin vs a control group receiving "usual care." Randomized, blinded, prospective trials are needed to assess the impact of hyperlipidemia as a risk factor, and the impact of its reduction in African Americans."
01/01/2015 - "He was prescribed and took pravastatin for almost 3 years to treat hyperlipidemia. "
07/01/2014 - "The combination is well tolerated and is indicated in patients with high risk and mixed hyperlipidemia who have controlled or are close to their objectives for LDL-c levels, using 40-mg pravastatin in monotherapy. "
|3.||Coronary Disease (Coronary Heart Disease)
03/01/2008 - "In this high-risk group, treatment with pravastatin is highly efficacious, reducing the odds of fatal coronary disease or nonfatal MI by approximately 75%, as compared with 25% in noncarriers or heterozygotes."
10/17/2000 - "Pravastatin treatment is effective in reducing coronary heart disease events in patients with high or low risk factor status and across a wide range of pretreatment lipid concentrations."
09/01/2007 - "SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients."
01/01/2002 - "The purpose of Holicos-PAT was to investigate the efficacy of serum lipid lowering by pravastatin against coronary heart disease (CHD) and cerebrovascular disease (CVD) in the Japanese population. "
12/01/2009 - "Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT)."
|4.||Coronary Artery Disease (Coronary Atherosclerosis)
03/15/1999 - "Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis."
08/01/2012 - "A 6-month prospective observational study was conducted among 114 patients with coronary artery disease (CAD) who were treated with pravastatin. "
06/01/2009 - "The present study demonstrated that an increase in BMI attenuated pravastatin-induced coronary atherosclerosis regression. "
10/15/2005 - "This study investigated the effects of pravastatin on the serum levels of MDA-LDL and coronary atherosclerosis. "
11/01/2002 - "The present study was designed to determine the association between treatment with pravastatin and the development of coronary collateral circulation as assessed by the Rentrop Score in patients with coronary artery disease (CAD) in a case-control study. "
10/01/2015 - "In addition, they suggest that application of pravastatin may be beneficial for prevention of atherosclerosis formation in hyperfibrinogenemia."
03/01/2002 - "Conversely, pravastatin treatment promoted significant improvement in endothelial function and reduced the progression of atherosclerosis. "
01/01/2002 - "Early and pronounced clinical efficacy of pravastatin demonstrated in trials with clinical endpoints is discussed and value of the drug for primary and secondary prevention of atherosclerosis stressed."
04/01/2009 - "Thus, the aim of the present study was to determine whether the action of pravastatin in preventing aortic atherosclerosis by attenuation of IFN-gamma action is dependent on STAT1. "
07/01/2006 - "Influences of age, sex, and LDL-C change on cardiovascular risk reduction with pravastatin treatment in elderly Japanese patients: A post hoc analysis of data from the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE)."
|1.||Transplantation (Transplant Recipients)
|2.||Heart Transplantation (Grafting, Heart)
|4.||Angioplasty (Angioplasty, Transluminal)
|5.||Drug Therapy (Chemotherapy)